🔥36氪•Freshcollected in 4m
BrainCo Launches Clinical Trial for BCI Hand Control System
💡Major milestone in BCI: First-of-its-kind fully wireless, implanted system enters clinical trials.
⚡ 30-Second TL;DR
What Changed
System features full implantation and wireless connectivity for BCI.
Why It Matters
Advances the practical application of BCI technology in medical rehabilitation, moving closer to commercial medical device certification.
What To Do Next
Follow the clinical trial results to understand the performance benchmarks of wireless BCI implants.
Who should care:Researchers & Academics
🧠 Deep Insight
AI-generated analysis for this event.
🔑 Enhanced Key Takeaways
- •BrainCo's BCI system utilizes a high-density electrode array designed to capture motor cortex signals with high signal-to-noise ratios, minimizing the need for external signal processing hardware.
- •The clinical trial is registered under the National Medical Products Administration (NMPA) GCP framework, marking a critical step toward Class III medical device certification in China.
- •The system incorporates proprietary AI-driven decoding algorithms that translate neural spikes into real-time motor commands for prosthetic hand control, reducing latency to sub-100ms levels.
- •Huashan Hospital's neurosurgery department is leading the implantation procedure, which utilizes a minimally invasive surgical approach to reduce recovery time for cervical spinal cord injury patients.
- •This 'three-all' system is designed to be compatible with long-term implantation, featuring biocompatible materials that mitigate glial scarring and signal degradation over time.
📊 Competitor Analysis▸ Show
| Feature | BrainCo (Three-All) | Neuralink (Telepathy) | Synchron (Stentrode) |
|---|---|---|---|
| Implantation | Fully Implanted | Fully Implanted | Endovascular (Minimally Invasive) |
| Connectivity | Fully Wireless | Fully Wireless | Fully Wireless |
| Primary Target | Cervical SCI / Hand Control | Motor Neuron Disease / General | Paralysis / Motor Control |
| Status | Clinical Trial (China) | Clinical Trial (US) | Clinical Trial (US/Australia) |
🛠️ Technical Deep Dive
- Electrode Array: High-density micro-electrode array targeting the primary motor cortex for precise neural signal acquisition.
- Data Transmission: Utilizes ultra-low-power wireless telemetry for data transfer, eliminating transcutaneous cables and reducing infection risk.
- Decoding Architecture: On-chip or edge-based neural decoding using deep learning models to map neural firing patterns to specific hand gestures (e.g., pinch, grasp).
- Power Management: Inductive charging system allowing for transdermal power transfer to the implanted unit.
- Biocompatibility: Encapsulated in medical-grade titanium or specialized polymers to ensure long-term stability within the intracranial environment.
🔮 Future ImplicationsAI analysis grounded in cited sources
BrainCo will seek NMPA approval for commercialization by 2028.
The initiation of GCP-registered clinical trials is a mandatory precursor to the multi-year regulatory review process required for Class III medical devices in China.
The system will expand to support lower-limb rehabilitation.
The modular nature of the neural decoding software allows for the integration of exoskeleton control, which is a logical progression for cervical spinal cord injury treatment.
⏳ Timeline
2015-01
BrainCo founded at the Harvard Innovation Lab.
2019-05
BrainCo unveils the Focus headband for educational and attention monitoring.
2023-11
BrainCo announces advancements in non-invasive BCI prosthetics at international medical forums.
2026-07
BrainCo initiates GCP-registered clinical trial for fully implanted BCI at Huashan Hospital.
📰
Weekly AI Recap
Read this week's curated digest of top AI events →
👉Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: 36氪 ↗